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      1. INTRODUCTION 
 
Tablets are solid preparations each containing a single dose of one or more active 
substances and usually obtained by compressing uniform volumes of particles. Tablets are 
intended for oral administration. Some are swallowed whole, some after being chewed, some 
are dissolved or dispersed in water before being administered and some are retained in the 
mouth where the active substance is liberated1. 
 
Several categories of tablets for oral use may be distinguished1   
 Uncoated tablets 
 Coated tablets 
 Effervescent tablets  
 Soluble tablets 
 Dispersible tablets  
 Orodispersible tablets  
 Gastro-resistant tablets  
 Modified-release tablets 
 
Oral routes of drug administration have wide acceptance up to 50-60% of total dosage 
forms. Solid dosage forms are popular because of ease of administration, accurate dosage, 
self medication, pain avoidance and most importantly the patient compliance. One of the 
important drawbacks of this dosage forms for some patients, is the difficulty to swallow. 
Drinking water plays an important role in the swallowing of oral dosage forms. Often times 
people experience inconvenience in swallowing conventional dosage forms such as tablet 
when water is not available, in the case of the motion sickness and sudden episodes of 
coughing during the common cold, allergic condition and bronchitis. For these reason, tablets 
that can rapidly dissolve or disintegrate in the oral cavity have attracted a great deal of 
attention. Orodispersible tablets are not only indicated for people who have swallowing 
difficulties, but also are ideal for active people.  
ODTs are known by various names such as “fast-melting, fast-dissolving, oral 
disintegrating or orodisperse”. The European Pharmacopoeia defines the term “orodisperse” 
as a tablet that can be placed in the mouth where it disperses rapidly before swallowing. Fast 
dissolving tablets are those when put on tongue disintegrate instantaneously releasing the 
drug which dissolve or disperses in the saliva. The faster the drug into solution, quicker the 
absorption and onset of clinical effect2. 
 
1.1. CRITERIA FOR FAST DISSOLVING DRUG DELIVERY SYSTEMS2, 3 
 
The tablets should 
 Not require water to swallow, but it should dissolve or disintegrate in the mouth in 
matter of seconds 
 Be compatible with taste masking 
 Be portable without fragility concern 
 Have a pleasant mouth feel 
 Leave minimum or no residue in the mouth after oral administration 
 Exhibit low sensitive to environmental condition as temperature and humidity 
 Allow the manufacture of the tablet using conventional processing and packaging 
equipments at low cost 
 
 
1.2. SALIENT FEATURES OF ORODISPERSIBLE DRUG DELIVERY SYSTEM2, 3 
 
 Convenience of administration and accurate dosing as compared to liquids. 
 Ease of administration to patients who refuse to swallow a tablet, such as paediatric 
and geriatric patients and, psychiatric patients. 
 No need of water to swallow the dosage from, which is highly convenient feature for 
patients who are traveling and do not have immediate access to water. 
 Good mouth feels properly of ODDS helps to change the basic view of medication as 
“bitter pill”, particularly for paediatric patients. 
 
 Some drugs are absorbed from the mouth pharynx and oesophagus as the saliva 
passes down into the stomach, in such cases bioavailability of drugs is increased. 
 Rapid dissolution of drug and absorption which may produce rapid, onset of action. 
 Pregastric absorption can result in improved bioavailability and as a result of reduced 
dosage, improved clinical performance through a reduction of unwanted effects. 
 Ability to provide advantages of liquid medication in the form of solid preparation. 
 
 
1.3. ADVANTAGES OF ORODISPERSIBLE TABLETS4,5 
 
  • No water needed 
  • No chewing needed 
  • Better taste 
  • Improved stability 
  • Suitable for controlled/sustained release actives 
  • Allows high drug loading. 
  • Ability to provide advantages of liquid medication in the form of solid preparation. 
  • Cost‐ effective 
  • Rapid drug therapy intervention 
  • High drug loading is possible. 
  • Have acceptable taste and pleasant mouth feeling. 
  • Leave minimum residue. 
 
 
 
 
 
 
 
               
 
FIGURE – 1   STEPS INVOLVED IN MOUTH DISSOLVING TABLETS 5 
 
1.4. LIMITATIONS TO ORODISPERSIBLE TABLETS5 
i) Drugs with relatively larger doses are difficult to formulate into ODTs e.g. antibiotics like 
ciprofloxacin with adult dose tablet containing about 500 mg of the drug. 
ii) Patients who concurrently take anticholinergic medications may not be the best candidates 
for ODTS. 
 
1.5. DRUG SELECTION CRITERIA 
The ideal characteristics of a drug for oral dispersible tablet include: 
 
 Ability to permeate the oral mucosa. 
 
 At least partially non-ionized at the oral cavity pH. 
 
 Have the ability to diffuse and partition into the epithelium of the upper GIT. 
 
 Short half life and frequent dosing drugs are unsuitable for orodispersible tablets 
(ODT). 
 
 Drug should have good stability in saliva and water. 
  Very bitter or unacceptable taste and odor drugs are unsuitable for orodispersible 
tablets(ODT). 
                                              
Excipients commonly used for ODT preparation4 
Mainly seen excipients in FDT are as follows at least one disintegrant, a diluent, a              
lubricant, and, optionally, a swelling agent, a permeabilizing agent,sweeteners, and 
flavorings. 
 
1.6. METHOD OF ADDITION OF DISINTEGRANTS5 
Disintegrants are substances or mixture of substances added to the drug formulation 
that facilitates the breakup or disintegration of tablet or capsule content into smaller particles 
that dissolve more rapidly than in the absence of disintegrants. Superdisintegrants are 
generally used at a low level in the solid dosage form, typically 1-10% by weight relative to 
the total weight of the dosage unit. Examples of superdisintegrants are croscarmellose, 
crospovidone, sodium starch glycolate which represent example of a cross-linked cellulose, 
cross-linked polymer and a cross-linked starch respectively. 
 
  
 
 
 
 
 
 
 
 
 
 
 
                       
             FIGURE -2: STAGES INVOLVED IN DISINTEGRATION 
                                          
     The ideal characteristics of a disintegrant has3 
 
1. High solubility 
 
2. Good gel formation 
 
3. Good molding and flow properties 
 
4.    No tendency to form complexes with the drugs  
 
5.  Good hydration capacity 
  
Disintegrants are essentially added to tablet granulation for causing the compressed tablet to 
break or disintegrate when placed in aqueous environment. 
 
 
 
 
There are three methods of incorporating disintegrating agents into the tablet: 
      1.   Internal addition (Intra granular) 
 
2. External addition (Extra granular) 
 
3. Partly Internal and External 
 
  In Internal addition method, the disintegrant is mixed with other powders before 
wetting the powder mixtures with the granulating fluid. Thus the disintegrant is incorporated 
within the granules. When these methods are used, part of disintegrant can be added 
internally and part externally. This provides immediate disintegrating agent within the 
granules produces further erosion of the granules to the original powder particles. 
           In External addition method, the disintegrant is added to the sized granulation with 
mixing prior to compression. The two-step method usually produces better and more 
complete disintegration than the usual method of adding the disintegrant to the granulation 
surface only3. 
 
TABLE NO: 1 NAME AND WEIGHT PERCENTAGE OF VARIOUS 
EXCIPIENTS 
 
Name of the excipients Percentage used 
 
Disintegrant 
 
Binder 
 
Antistatic agent 
 
Diluents 
 
1 to 15 % 
 
5 to 10 % 
 
0 to 10 % 
 
0 to 85% 
 
 
 
1.7. MECHANISM INVOLVED IN ORODISPERSIBLE TABLET TECHNOLOGIES 
6: 
Disintegrant is a  substance or  mixture of substances added to tablets to facilitate its 
break up or disintegration. The active constituents must be released from the tablet as 
efficiently as possible to allow its rapid action. The basic approaches used in fast dissolving 
tablet technologies are increasing the porous structure of the tablet matrix and incorporating 
disintegrating agents or highly water soluble excipients in the tablet formulation. The basic 
function of a disintegrant used in the formulations of tablets are to oppose the physical forces 
and efficacy of the tablet binder which act during the compression of tablet. The process 
involved in the production of a homogeneous suspension or solution of tablet where the tablet 
is broken down into smaller particles is based on: 
a) By capillary action  
b) By swelling 
c) Because of heat of swelling 
d) Due to release of gases 
e) By enzymatic actions 
      f )  Due to disintegrating particle/particle repulsive force 
f) Due to deformation  
 
 
 
 
 
 
 
 
 
 
MECHANISM OF ACTION: 
                                    
                                                                      Figure 1 
                                 FIGURE-3:  Mechanism of action of Orodispersible tablet                                                                       
                                                                            
 
When such tablets are placed in oral cavity, saliva quickly penetrates into the pores to 
cause rapid tablet disintegration. Recent market studies indicate that more than half of the 
patient population prefers ODTs to other dosage forms. Most consumers would ask their 
doctors for ODTs (70%), purchase ODTs (70%), or prefer ODTs over regular tablets or 
liquids (>80%).The US Food and Drug Administration Center for Drug Evaluation and 
Research (CDER) defines, in the ‘Orange Book’, an ODT as “a solid dosage form containing 
medicinal substances, which disintegrates rapidly, usually within a matter of seconds, when 
placed upon the tongue”. 
 
 
 
 
 
 
 
 1.8. TECHNOLOGIES USED TO MANUFACTURE ORODISPERSIBLE TABLETS6 
The technologies used to manufacture mouth dissolving tablets can be classified as:  
                                             
                                            TECHNOLOGIES 
 
                                                       
 
 
 
                                                                                                  
 
      1)  Freeze drying                                                     1) Zydis technology          
      2) Direct compression                                             2) Orasolv technology 
      3) Spray drying                                                       3) Durasolv technology 
      4) Tablet molding                                                   4) Flash dose technology 
      5)  Sublimation                                                       5) Flash tab technology 
      6) Effervescent method                                          6) Wow tab technology                                                                                                                     
      7) Phase transition process                                     7) Lyoc technology 
      8) Melt granulation                                                 8) Pharmaburst technology                        
 
 
 
 
 
 
 
 
 
1.8.1 CONVENTIONAL TECHNOLOGIES 
1. Freeze Drying6 
          ZYDIS® (R.P. Scherer, Swindon, UK), using freeze drying processes is one of the first 
generations of fast disintegrating dosage forms. There are approximately 12 marketed 
PATENDED 
TECHNOLOGIES 
CONVENTIONAL 
TECHNOLOGIES 
ZYDIS® products, including lorazepam, piroxicam, loperamide, loratidine, enalapril. A 
process in which water is sublimated from the product after freezing.  
 
Lyophilization is a pharmaceutical technology which allows drying of heat sensitive drugs 
and biological at low temperature under conditions that allow removal of water by 
Sublimation. Lyophilization results in preparations, which are highly porous, with a very high 
specific surface area, which dissolve rapidly and show improved absorption and 
bioavailabity.                                                          
 
2. Direct Compression8 
It is the easiest way to manufacture tablets. Conventional equipment, commonly available 
excipients and a limited number of processing steps are involved in direct compression. Also 
high doses can be accommodated and final weight of tablet can easily exceed that of other 
production method. 
         
 a) Superdisintegrants2 
The addition of superdisintegrants mainly affects the rate of disintegration in many 
ODT technologies based on direct compression and hence the dissolution is also affected by 
its action. The disintegration can be accelerated by the addition of ingredients like 
effervescent agents and water – soluble excipients 
 
 b) Sugar Based Excipients2 
This is another method to manufacture ODT using direct compression. The addition 
of sugar based excipients like bulking agents e.g. dextrose, maltose, mannitol, isomalt, 
fructose, polydextrose and xylitol, which provide sweetness and high aqueous solubility 
thereby imparting a pleasant mouth feel and taste masking property. On the basis of moulding 
and dissolution rate, Mizumito et. Al, have classified sugar-based into two types. 
Type 1  Saccharides (mannitol and lactose) which exhibit low mould ability but with high 
dissolution rate. 
Type 2  Saccharides (maltilol and maltose) which exhibit high mould ability but with low 
dissolution rate. 
 
Advantages of direct compression8 
 Requires fewer unit operations compared with wet granulation (shorter processing 
time and lower energy consumption). 
 Fewer stability issues for actives that are sensitive to heat or moisture. 
 For certain compounds, faster dissolution rates may be generated from tablets 
prepared by direct compression compared with wet granulation. for example, 
norfloxacin. 
 Fewer excipients may be needed in a direct compression formula. 
 
Disadvantages of direct compression8 
 Issues with segregation – these can be reduced by matching the particle size and 
density of the active drug substance with excipients. 
 In general, the drug content is limited to approximately 30% or approximately 50 mg. 
 Not suited for poorly flowing drug compounds. 
 Static charges may develop on the drug particles or excipients during mixing, which 
may lead to agglomeration of particles producing poor mixing. 
 
3. Spray Drying3,6 
The formulations contained hydrolyzed and unhydrolyzed gelatin as a supporting agent 
for the matrix, mannitol as a bulking agent and sodium starch glycolate/croscarmellose as a 
disintegrant. Disintegration and dissolution were further enhanced by adding an acid (e.g., 
citric acid) or an alkali (e.g., sodium bicarbonate). The suspension of above excipients was 
spray‐dried to yield a porous powder which was compressed into tablets. Tablets 
manufactured by this method disintegrated in < 20 secs in an aqueous medium. 
 
 
 
4. Tablet Molding6 
In this method, molded tablets are prepared by using water-soluble ingredients so that the 
tablets dissolve completely and rapidly. The powder blend is moistened with a 
hydro‐alcoholic solvent and is molded into tablets under pressure lower than that used in 
conventional tablet compression. The solvent is then removed by air‐drying. Molded tablets 
are very less compact than compressed tablets. These possess porous structure that enhances 
dissolution. 
 5. Sublimation3,6 
Sublimation has been used to produce ODTs with high porosity. A porous matrix is 
formed by compressing the volatile ingredients along with other excipients into tablets, which 
are finally subjected to a process of sublimation. Inert solid ingredients with high volatility 
(e.g., ammonium bicarbonate, ammonium carbonate, benzoic acid, camphor, hexamethylene 
tetramine, naphthalene, phthalic anhydride, urea and urethane) have been used for this 
purpose. Solvents such as cyclohexane and benzene were also suggested for generating the 
porosity in the matrix. 
 
6. Effervescent Method7 
Orodispersible tablets are also prepared by effervescent method by using sodium 
bicarbonate and tartaric acid of concentration 12 % w/w along with super disintegrants like 
pregelatinised starch, crospovidone, croscarmellose, sodium starch glycolate. First, sodium 
bicarbonate and tartaric acid were preheated at a temperature of 80ºC to remove 
absorbed/residual moisture and thoroughly mixed in mortar. Finally, the blends are 
compressed in the punch. 
 
7. Phase Transition Process7 
In this process the combination of low and high melting point sugar alcohols, along with a 
transition of phase in the manufacturing process are important for formulating ODTs. For this 
transition, special equipments are not employed. ODTs were produced by compressing 
xylitol at melting point; 93.95º C and erythritol at melting point ; 122ºC and then heating at 
about 93º C for 15 min. The median pore size of the tablets along with hardness was 
increased after heating. The increased tablet hardness does not depend on the crystal state or 
the lowering melting point of sugar alcohol. 
 
 
8. Melt Granulation7 
This is a process in which with the help of a meltable binder, pharmaceutical powders are 
efficiently agglomerated. The advantage of the technique in comparison to the traditional 
granulation is that water or organic solvents are not needed as there is no drying step involved 
in it. Compared to wet granulation, the process is less time consuming and uses less energy. 
This technique can be applied for enhancing the dissolution rate of drugs which have poor 
water solubility like grisiofulvin. To prepare ODT with sufficient mechanical integrity, the 
approach uses the hydrophilic waxy binder such as PEG-6-stearate and Superpolystate. 
Superpolystate is a waxy material which helps tablet disintegration as it melts in the mouth 
and acts as a binder. It also solubilizes rapidly without any residues. 
 
1.8.2. PATENDED TECHNOLOGY 
 
1. Zydis technology9 
Zydis, the best known of the fast-dissolving/disintegrating tablet preparations was the first 
marketed new technology tablet. The tablet dissolves in the mouth within seconds after 
placement on the tongue. A Zydis tablet is produced by lyophilizing or freeze-drying the drug 
in a matrix usually consisting of gelatin. The product is very light weight and fragile, and 
must be dispensed in a special blister pack. Patients should be advised not to push the tablets 
through the foil film, but instead peel the film back to release the tablet. The Zydis product is 
made to dissolve on the tongue in 2 to 3 seconds. The Zydis formulation is also self-
preserving because the final water concentration in the freeze-dried product is too low to 
allow for microbial growth. 
 
Desired characteristics of zydis technology: 
i. Drug should be chemically stable 
ii. Particle size lesser than 50 µm 
iii. Water insoluble 
iv. Dose for water soluble drugs is limited (60 mg)     
 
    2.  Flash dose technology2, 9 
Flash dose technology has been patented by Fuisz. Nurofen melt let, a new form of 
ibuprofen as melt-in-mouth tablets, prepared using flash dose technology is the first 
commercial product launched by Biovail Corporation. Flash dose tablets consist of self 
binding shear form matrix termed as “floss”. Shear form matrices are prepared by flash heat 
processing. 
 
    3.   Flash Tab Technology9 
The technology is patented by Ethypharm France. This involves granulation of 
excipients by wet or dry granulation method followed by compression into tablets. Two types 
of excipients are employed in this technology. Reticulated polyvinylpyrrolidine or carboxy 
methyl cellulose, starch, modified starch, microcrystalline cellulose, carboxy methylated 
starch, etc are some of the disintegrating agents included. Satisfactory physical resistance is 
present in these tablets. 
 
4. Durasolv technology9 
Durasolv is the patented technology of CIMA labs. The tablets made by this technology 
consist of a drug, fillers and a lubricant. Tablets are prepared by using conventional tableting 
equipment and have good rigidity. These can be packed into conventional packaging system 
like blisters. Durasolv is an appropriate technology for products requiring low amounts of 
active ingredients. 
 
5. Orasolv technology2 
       CIMA labs have been developed orosolve technology. In this system active medicament 
is taste masked. It also contains effervescent disintegrating agent. Tablets are made by direct 
compression technique at low compression force in order to minimize oral dissolution time. 
Conventional blenders and tablet machine is used to produce the tablets. The tablets produced 
are soft and friable and packaged in specially designed pick and place system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              2. LITERATURE SURVEY 
 
2.1. REVIEW OF ORODISPERSIBLE TABLET 
 
 Prakash Goudanavar  et.al,  (2011)  The present study was aimed at developing and 
evaluating fast disintegrating tablets of Granisetron HCl using natural superdisintegrants like 
Plantago ovata, gum karaya and agar and synthetic superdisintegrants like Indion 234, 
croscaramellose sodium and crospovidone in different concentration. Fast disintegrating 
tablets were prepared by direct compression method. Effect of superdisintegrants on wetting, 
disintegration and dissolution parameters were studied. Fast disintegrating tablets were 
characterized by Fourier Transform Infrared (FTIR) spectroscopy and Differential Scanning 
Calorimetry (DSC) 10. 
 
Metker Vishal et.al, (2011)  The purpose of this investigation was to develop mouth 
dissolving tablets of Lornoxicam using KYRON T-314 (Polacrillin Potassium) as a novel 
Superdisintegrant. Mouth dissolving tablets of lornoxicam were prepared by wet granulation 
technique using KYRON T-314 as superdisintegrant and menthol as subliming agent. The 
present study demonstrated potentials for rapid absorption, improved bioavailability, 
effective therapy and patient compliance11.    
 
Abdul S.Althaf   et.al, (2011)    Mouth dissolving tablets of sildenafil citrate were prepared 
by wet granulation and direct compression method by superdisintegrant addition. Eight 
batches (B1‐B8) of mouth dissolving tablets of sildenafil citrate were prepared by using 
crospovidone, ac-di-sol in different concentrations. All the formulations were evaluated for 
weight variation, hardness, friability, drug content, in‐vitro disintegration time, wetting time, 
in‐vitro dissolution etc., and batch B8 shows the values within the limits. Formulation B8 with 
5% crospovidone, Ac-di-sol showed the less disintegration time (32 seconds) and less wetting 
time (41.5 seconds) 12. 
 
 
C. Patil  and S. Das  et.al, (2011)  The demand for orally disintegrating tablets of 
lamotrigine has been growing during the last decade especially for the geriatric and pediatric 
patients. Lamotrigine is a recognized drug for epilepsy, so development of an ODT of 
lamotrigine and to evaluate the effect of various superdisintegrants on its disintegration time 
and release profile was the prime objective of this research work. Tablets were prepared by 
direct compression technique using 3 different superdisintegrants. Sodium starch glycolate, 
croscarmellose sodium and crospovidone XL-10 were used as superdisintegrants in 
combinations to achieve optimum release profile, disintegration time and hardness. Direct 
compression process was selected for this formulation of ODT tablets, because porous nature 
is more in direct compression blend than wet granulation blend, so it will give faster 
disintegration. Microcrystalline cellulose was used as diluent13.  
 
Prakash Goudanavar et.al,  (2011)  The present study aimed at preparing orodispersible 
tablets of lamotrigine by forming inclusion complex with hydroxypropyl β‐cyclodextrin 
(HPβCD) employing kneading method. The complex was compressed into tablets along with 
superdisintegrants such as Kyron T‐314, Sodium starch glycolate, Indion 414, croscarmellose 
sodium and crospovidone in different concentration. Bitter taste of drug is successfully 
masked by HPβCD complex and is also useful to enhance the solubility which was confirmed 
by phase solubility analysis. Orodispersible tablets were characterized by Fourier Transform 
Infrared (FTIR) Spectroscopy, Differential Scanning Calorimetry (DSC) and Powder X‐ray 
Diffraction Analysis (PXRD). The Result revealed that F6 had shown short dispersion time 
with maximum drug release in 12 minutes. Formulation containing higher concentration of 
Indion 414 decreases disintegration time (22.71 sec) and optimize the drug release (99.09% 
in 12 minutes)14. 
 
Tejvir kaur et.al, (2011) Recent advances in Novel Drug Delivery Systems (NDDS) aim for 
designing dosage forms, convenient to be manufactured and administered, free of side 
effects, offering immediate release and enhanced bioavailability, so as to achieve better 
patient compliance. Though oral drug delivery systems, preferably, tablets are the most 
widely accepted dosage forms, for being compact, offering uniform dose and painless 
delivery. Yet, dysphagia is the most common disadvantage of conventional tablets. This is 
seen to afflict nearly 35% of the general population and associated with a number of 
conditions, like Parkinsonism, mental disability, motion sickness, unconsciousness, 
unavailability of water etc. To overcome such problems, certain innovative drug delivery 
systems, like ‘Mouth Dissolving Tablets’ (MDT) have been developed. These are novel 
dosage forms which dissolve in saliva within a few seconds, when put on tongue. Such 
MDTs can be administered anywhere and anytime, without the need of water and are thus 
quite suitable for children, elderly and mentally disabled patients5. 
 
Dr. Lakshmi CSR et.al, (2011)   Atenolol is a β1 selective antagonist without membrane 
stabilizing or intrinsic sympathomimetic activities. Administration of conventional tablets of 
atenolol has been reported to exhibit fluctuation in the plasma drug levels, resulting either in 
manifestation of side effects or reduction in drug concentration at the receptor site. In the 
present study an attempt has been made to prepare melt-in-mouth tablets (MMT) of atenolol 
with enhanced dissolution rate. The fast dissolving tablets of atenolol was prepared using 
various concentrations of subliming agents like ammonium bicarbonate, camphor, menthol, 
thymol, phthalic anhydride by direct compression method15. 
 
Sharma Shailesh et.al, (2010)   The purpose of this research was to develop mouth dissolve 
tablets of domperidone. Tablet containing domperidone, camphor and crospovidone were 
prepared by direct compression technique. In the investigation, a 32 full factorial design was 
used to investigate the joint influence of 2 formulation variables amount of camphor and 
crospovidone. Camphor was sublimed from these tablets by exposure to vacuum. The tablets 
were evaluated for percent friability and disintegration time16. 
 
P. V. Swamy  et.al,  (2010)    The aim of the present study was to develop orodispersible 
tablets of diethylcarbamazine citrate (anthelmintic).In the effervescent method mixture of 
sodium bicarbonate and tartaric acid along with treated agar were used as disintegrants.  The 
present study clearly demonstrates that orodispersible tablets of diethylcarbamazine citrate 
could be successfully prepared by direct compression method in a cost effective manner 
employing treated agar. The use of effervescent mixture further assists in taste masking17.  
 
 
Mohanchandran P.S et.al (2010)  This formulation has been made for the development of 
rapidly disintegrating oral tablets of amlodipine besylate by direct compression method. In 
this study, fast dissolving tablets of amlodipine besylate using different superdisintegrants 
were prepared by direct compression method. FDT’s were evaluated for its physicochemical 
properties and in vitro dissolution. Effect of different superdisintegrants on disintegration 
behaviour of tablets was evaluated in phosphate buffer pH 7.2. All formulations were 
evaluated for pre‐compression and post‐ compression parameters. Wetting time of 
formulations containing croscarmellose sodium was least and tablets showed fastest 
disintegration. FT‐IR studies revealed that there was no physico‐chemical interaction 
between amlodipine besylate and other excipients. Of the twelve formulations studied, F10 
showed short dispersion time with maximum drug release in 30 minutes18. 
 
A. Prameela rani   et.al, (2010)   In the present study an attempt has been made to prepare 
fast disintegrating tablets of Metformin.Hcl in the oral cavity with enhanced dissolution rate. 
The tablets were prepared with Isphagula husk, natural superdisintegrant and crospovidone, 
synthetic superdisintegrant. The pure drug and formulation blend was examined for angle of 
repose, bulk density, tapped density, compressibility index and hausner’s ratio. The tablets 
were evaluated for hardness, tensile strength, drug content, friability and were found 
satisfactory. The disintegration time in the oral cavity was also tested and was found to be 
around 10sec. Based on dissolution rate the disintegrants can be rated as Isphagula husk > 
Crosspovidone. Hence Isphagula husk was recommended as suitable disintegrant for the 
preparation of direct compression melt‐in‐mouth tablets of Metformin.Hcl19. 
 
Kalpesh K. Mehta   et.al, (2010)  The purpose of this research was to develop fast 
dissolving tablets of nimesulide containing natural Lepidium sativum (family: Cruciferae) 
known as asaliyo and widely used as herbal medicine and pharmaceutical excipient as 
disintegrating agent. The mucilage was extracted from seeds of Lepidium sativum and was 
used to develop the fast dissolving tablet of nimesulide. The extracted mucilage was 
characterized for weight loss on drying, particle size, pH of solution, swelling ratio, bulk and 
tapped density, compressibility index, viscosity and Angle of repose. The disintegration 
property of extracted mucilage in FDTs was compared with widely used superdisintegrants 
like Sodium starch glycolate (SSG), Kyron T314, Ac Di Sol. The prepared FDTs were 
evaluated for uniformity of weight, hardness, tablet thickness, Percentage friability, Wetting 
time, in vitro disintegration time and in vitro dissolution20. 
 
Howida Kamal Ibrahim and Doaa A. El-Setouhy  (2010)     Valsartan orodispersible 
tablets have been developed at 40-mg dose, with the intention of facilitating administration to 
patients experiencing problems with swallowing and hopefully, improving its poor oral 
bioavailability. Work started with selecting drug compatible excipients depending on 
differential scanning calorimetric analysis. A full factorial design was adopted for the 
optimization of the tablets prepared by freeze-drying technique. The effects of the filler type, 
the binder type, and the binder concentration were studied. The different tablet formulas were 
characterized for their physical properties, weight variation, disintegration time, surface 
properties, wetting properties, and in vitro dissolution. Amongst the prepared 27 tablet 
formulas, formula number 6 (consisting of 4:6 valsartan: mannitol and 2% pectin) was 
selected to be tested in vivo21. 
 
V.S. Mannur et.al,  (2010)    Prepared ranitidine dispersible tablets using a  direct 
compression method was used to prepare these types of tablets using different super 
disintegrants viz. sodium carboxy methyl cellulose (SCMC), pregelatinised starch and 
sodium starch glycolate (SSG). Mannitol was employed to improve the mouth feel and 
aspartame to improve the taste. The formulations were evaluated for both precompression 
and post compression parameters. The tablets showed satisfactory hardness and the drug 
content were also found to within the IP range for all the formulations. The tablets 
disintegrated within 19 to 22 seconds and wetting time of the tablets was found to be between 
17 to 20 seconds22. 
 
Jayashri G.Mahore et.al, (2010) In the present work, orodispersible tablets of 
metoclopramide HCl were designed by preparing tasteless complexes of metoclopramide HCl 
with weak cation ion exchange resins (Indion 234). The ion exchange complex were prepared 
by the batch  process using  activated Indion-234 with a drug: resin ratios 1:1,1:2 and 1:3 (% 
w/w)  and IR analysis, assay content and  decomplexation studies give evidence of complex 
formation. Drug shows maximum complexation with resin in pH range 4-6, while activation 
of  ion exchange resin  affects the percent  drug loading. Drug release from drug: resin 
complex in salivary pH was in sufficient to impart bitter taste. A study on super-disintegrants 
i.e., croscarmellose sodium, sodium starch glycolate, crospovidone along with directly 
compressible mannitol to enhance mouth feel23.   
 
Niladri Shekhar Dey  et.al,  (2010)   The present research work has been carried out for an 
optimized formulation of co-processed directly compressible vehicles in the preparation of 
the paracetamol mouth fast dissolving tablets (MFDTs). Paracetamol was chosen due to its 
poor compression properties. Co-processed direct compressible vehicles such as 
microcrystalline cellulose spray dried lactose and pearlitol were taken in different ratios such 
as (10:90, 25:75, 50:50, 75:25 & 90:10) using crospovidone as superdisintegrant. The effects 
of other superdisintegrants were studied in the best formulation F15. Optimized formulation 
F15 B was found to be optimum compressibility characteristics hardness 4 kg/cm2 with fast 
disintegration (9 sec) compare to other formulations24. 
 
Pooja Mathur et.al, (2010)   The desire of improved palatability in orally administered 
products has prompted the development of numerous formulations with improved 
performance and acceptability. Orally disintegrating tablets (ODTs) have received ever-
increasing demand during the last few decades, and the field has become a rapidly growing 
area in the pharmaceutical industry. The unique property of mouth dissolving tablet is that 
they are rapidly disintegrating and/or dissolving and release the drug as soon as they come in 
contact with saliva, thus obviate the requirement of water during administration. This article 
reviews the earlier applications and methodologies of taste masking and also emphasize on 
the recent developments and approaches of bitterness reduction for orally used 
pharmaceuticals25.  
 
Suhas M. Kakade et.al, (2010)  The present work, orodispersible tablets of losartan 
potassium were design with a view to enhance the patient compliance and provide a quick 
onset of action. Losartan potassium is an angiotension receptor antagonist, used in the 
management of hypertension. It has low bioavailability due to its first pass metabolism. 
Hence the main objective of the study was to formulate orodispersible tablets of losartan 
potassium to achieve a better dissolution rate and improve the bioavailability of the drug. The 
tablets are prepared by direct compression method by using the superdisintegrants such as 
polyplasdone XL 10 ,croscarmellose sodium and explotab in different concentration and 
evaluated for the pre-compressibility parameters26.  
 
Siraj sheikh (2010)   Fast Disintegrating tablets have started gaining popularity and 
acceptance as new drug delivery systems, because they are easy to administered and lead to 
better patient compliance. Usually, elderly people experience difficulty in swallowing the 
conventional dosage forms such as tablets, capsules, solutions and suspensions because of 
tremors of extremities and dysphagia. Fast‐dissolving drug delivery systems may offer a 
solution for these problems. Recent development in fast disintegrating technology mainly 
works to improve the disintegration quality of these delicate dosage forms without affecting 
their integrity. This article focuses on the patented technologies available and the advances 
made so far in the field of fabrication of fast disintegrating tablets. Apart from the 
conventional methods of fabrication, this review also provides the detailed concept of some 
unique technologies like freeze drying, direct compression, spray drying, tablet molding, 
sublimation, fast dissolving films cotton candy process, along with their advantages and 
limitations8. 
 
Brahmeshwar Mishra et.al, (2009)     This article focuses on the technologies available and 
the advances made so far in the field of fabrication of mouth dissolving tablets. Apart from 
the conventional methods of fabrication, this review also provides the detailed concept of 
some unique patented technologies like Zydis, Lyoc, Quicksolv, Orasolv, Durasolv, Flash 
tab, Oraquick, Wow tab and Zip let along with their advantages and limitations27. 
 
Galal El-Mahrouk et.al, (2009)     Meloxicam is a non-steroidal anti-inflammatory drug with 
highly variable bioavailability due to its poor aqueous solubility and dissolution. This work 
aimed to improve meloxicam bioavailability by formulating it in orodispersible capsules 
containing a soluble complex of the drug with beta-cyclodextrin. Complexes were prepared 
by different methods and characterized by differential scanning calorimeter, X-ray 
diffraction, infrared spectroscopy and dissolution efficiency studies. Orodispersible capsule 
shells were prepared from conventional hard gelatin capsule shells by freeze-drying and 
evaluated by image analysis microscopy and moisture content estimation28.  
 
Debjit Bhowmik   et.al, (2009)     This tablet format is designed to allow administration of 
an oral solid dose form in the absence of water or fluid intake. Such tablets readily dissolve or 
disintegrate in the saliva generally within <60 seconds. Fast or mouth dissolving tablets have 
been formulated for pediatric, geriatric, and bedridden patients and for active patients who 
are busy and traveling and may not have access to water. Such formulations provide an 
opportunity for product line extension in the many elderly persons will have difficulties in 
taking conventional oral dosage forms (viz., solutions, suspensions, tablets, and capsules) 
because of hand tremors and dysphagia2.  
 
Radke R.S.    et.al, (2009)    The aim of this investigation was to prepare orodispersible 
tablets of baclofen using various concentrations of superdisintegrant agents like Ac-Di-Sol, 
crospovidone, sodium starch glycolate by direct compression method. Nine formulations 
having superdisintegrants at different concentration levels were prepared. These tablets were 
evaluated for drug content, weight variation, friability, hardness, wetting time and in vitro 
disintegration time. Among the formulations tablets of batch F3 containing Ac-Di-Sol 
showed superior organoleptic properties along with excellent in-vitro disintegration time and 
drug release as compare to other formulations29. 
 
Ravi Kumar et.al, (2009)  The purpose of this investigation was to develop fast dissolving 
tablets of haloperidol using camphor as a subliming agent. Orodispersible tablets of 
haloperidol were prepared by wet granulation technique using camphor as subliming agent 
and sodium starch glycolate together with croscarmellose sodium as superdisintegrants. 
Camphor was sublimed from the granules by exposing the granules to vacuum. The porous 
granules were then compressed in to tablets. Alternatively, tablets were first prepared and 
later exposed to vacuum. The formulations were evaluated for weight variation, hardness, 
friability, drug content, wetting time, in vitro and in-vivo dispersion, mouth feel and in vitro 
dissolution. All the formulations showed low weight variation with dispersion time less than 
45 seconds and rapid in vitro dissolution30. 
 
 
Biraju patel et.al, (2009)   In the present work, fast dissolving tablets of glipizide were 
prepared by direct compression method with a view to enhance patient compliance. Two 
superdisintegrants viz, crospovidone and croscarmellose sodium (4%, 5%, 6%) with different 
binders viz, pvp k-30 and pregelatinized starch (3%)  were used. The prepared batches of 
tablets were evaluated for hardness, friability, and weight variation, disintegration, wetting 
time, drug content and in vitro dissolution studies. Based on evaluating parameters, 
formulation prepared by using 5% croscarmellose sodium with 3% PVPK30 was  selected  as 
optimized formulation. Finally, the optimized formulation was compared with marketed 
conventional formulation. Stability studies were carried out at 25ºC / 60% RH and 40ºC / 
75% RH for optimized formulation for 2 months31. 
 
V.Balamuralidhara et.al, (2009)   In present study an attempt was made to formulate 
orodispersible tablets of rabeprazole. Tablets were prepared by direct compression method 
using diluents and various disintegrants. Tablets were also prepared using treated agar (TAG) 
powder as one of the disintegrant. A total number of ten formulations were prepared and 
evaluated. Along with physicochemical parameters, the tablets were also evaluated for 
special parameters like wetting time, in vitro dispersion time, in vitro disintegration and in 
vitro drug release. A better disintegration was observed in formulation OT1, OT2, OT5 and 
OT6 containing crospovidone and croscarmellose sodium32. 
 
Mukesh et.al, (2008)   The ODT should disperse/disintegrate in less than three minutes. The 
basic approach used in development of MDT is the use of superdisintegrants like cross linked 
carboxymethylcellulose (croscarmeliose), sodium starch glycolate (Primo gel, Explotab), 
polyvinylpyrolidone (polyplasdone) etc. which provide instantaneous disintegration of tablet 
after putting on tongue, thereby releasing the drug in saliva. The bioavailability of some 
drugs may be increased due to absorption of drugs in oral cavity and also due to pregastric 
absorption of saliva containing dispersed drugs that pass down into the stomach9. 
 
S.R. Shahi et.al, (2008)   Etoricoxib is a novel, selective second generation cyclo-oxygenase-
2 inhibitor administered orally as an analgesic and anti-inflammatory drug that is used for the 
treatment of osteoarthritis, rheumatoid arthritis and gouty arthritis. The poor aqueous 
solubility of the drug leads to variable dissolution rates. In the present investigation an 
attempt has been made to prepare oro-dispersible tablets of etoricoxib with enhanced 
dissolution rate. The another purpose of the present investigation was to evaluate effect of 
superdisintegrants like crospovidone, (Polyplasdone XL), croscarmellose Sodium (Ac-Di-
Sol) and sodium starch glycolate (Primojel) on dissolution of poorly soluble, selective COX-
2 inhibitor in oro-dispersible tablets33. 
 
Vijay Sharma et.al, (2008)    The  purpose of this study was to develop a dosage form that 
was easy to administer and provides rapid release of the drug roxithromycin, using modified 
polysaccharides as rapidly disintegrating excipients. Modified polysaccharides co grinded 
treated agar (C-TAG) and co grinded treated guar gum (C-TGG) were prepared by subjecting 
pure polysaccharides namely agar and guar gum respectively to sequential processes of 
wetting, drying and co grinding with mannitol (1:1). The modified polysaccharides were 
characterized by scanning electron microscopy and diffuse reflectance spectroscopy and 
evaluated for particle size distribution, derived properties, swelling index and 
biodegradability34. 
 
 
 2.2. REVIEW OF ONDANSETRON HYDROCHLORIDE  
 
Prabakaran. L et.al, (2011)   The purpose of this research was to introduce and evaluate 
natural excipient that has versatile property in the oral disintegrant and immediate release 
formulations. This natural excipient was used as disintegrant, binder, and diluent in the 
formulation of orodispersible tablets of some model drugs such as Ondansetron HCl (OND), 
Propranolol (PNL) and Gabapentin (GP).All the formulations are subjected for in vitro 
evaluations such as wetting time, water absorption ratio, in vitro dispersion time and 
disintegration time, etc. Therefore, we conclude that the natural excipient proposed can be 
used as binder, diluent and disintegrant in oral disintegrating tablets and immediate release 
dosage forms. Mainly the natural excipient used is biocompatible, cost effective and provides 
as nutrition supplements35. 
 
P. K. Lakshmi et.al, (2011)  The main objective of this study was to formulate and evaluate 
the orodispersible tablets of ondansetron hydrochloride with synthetic and natural 
superdisintegrants. Various formulations were prepared by direct compression using different 
concentrations of natural superdisintegrant i.e. isolated mucilage of Plantago ovata and 
synthetic superdisintegrants namely Kyron T-314, crospovidone, and croscarmellose sodium 
ranging from 0.4% to 2%. The initial compatibility studies between the drug and excipients 
were carried out using FTIR spectroscopy. The blend was evaluated for additive properties. 
The tablets were evaluated for physical parameters and in vitro drug release. The 
disintegration time and in vitro drug release of optimized formulation (FK5) was compared 
with that of marketed formulation. The disintegration time was found to be 32 sec as 
compared to 49 sec for marketed formulation36. 
 
Sunil H. Makwana et.al,  (2010)  The demand for mouth dissolving tablets has been 
growing, during the last decade especially for geriatric and pediatric patients because of 
swallowing difficulties. The purpose of this research was to mask the intensely bitter taste of 
ondansetron HCl and to formulate a orodispersible of the taste-masked drug. Taste masking 
was done by complexing ondansetron HCl with indion204 in different ratios by the solvent 
evaporation. Drug- resin complex were optimized by considering parameters such as 
optimization of resin concentration, optimization of swelling time, optimization of stirring 
time, optimization of pH and optimization of temperature on maximum drug loading. The 
effects of variables were observed on maximum amount of the drug loading. During 
preparation of drug resin complex (resinate), the other variables were kept constant. The 
resinate was evaluated for taste masking, characterized by X-Ray diffraction and infra red 
spectrometer. In vitro drug release study of taste masked tablet showed that more than 90 % 
of the drug release within 20 minutes. Thus, results conclusively demonstrated successful 
masking of taste and rapid disintegration of the formulated tablets in the oral cavity37. 
 
Prajapati R.H. et.al (2010)    The purpose of this research was to mask the intensely bitter 
taste of ondansetron Hcl by complexing with indion204 resin by the solvent evaporation and 
to formulate a mouth dissolving tablets of the taste-masked drug. Tablets were formulated by 
direct compression method using different superdisintegrants like Polyplasdone XL-10 &  
sodium starch glycolate (SSG) in different concentration, diluents like mannitol, 
microcrystalline cellulose  (MCC 112), sweetening agent aspartame, flavoring agents like 
peppermint and vanilla, lubricant  magnesium Stearate & glidant aerosil. All formulations 
were evaluated for disintegration time, wetting time, percentage friability, Content uniformity 
and in vitro dissolution rate. Formulations with 7% Polyplasdone XL-10 showed the 
disintegration time 14 seconds and wetting time 25 seconds. In vitro drug release study of 
taste masked tablet showed complete drug release within 10 minutes & successful masking of 
taste and rapid disintegration of the formulated tablets in the oral cavity38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2.3. DRUG PROFILE39, 40 
 
Drug                             :  Ondansetron Hydrochloride 
 
Molecular formula     :    C18H19N3O 
 
Structure                     : 
 
 
 
 
 
 
                                                                     
Chemical Name    : 1, 2, 3, 9-Tetrahydro-9-methyl-3-[(2-methyl-1h-imidazole-1-  
                                 yl )methyl]-4H-carbazol-4-one hydrochloride  
 
Molecular Weight: 293.326 g/mol 
 
Description           : A white or whitish yellow crystal powder 
 
Category               : Histamine 5-HT3 receptor antagonists 
 
Dose                      : 4mg and 8 mg for oral dose 
 Solubility              : Freely soluble in water 
 
 
Mode Of Action : Ondansetron is a selective serotonin 5-HT3 receptor antagonist. The 
antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors 
present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This 
inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting 
center, likely indirectly at the level of the area postrema, as well as through  direct inhibition 
of serotonin activity within the area postrema and the chemoreceptor trigger zone.   
 
Pharmacodynamics: Ondansetron is a potent, chemotherapeutic agents and radiotherapy 
may cause release of 5HT in the small intestine initiating a vomiting reflex by activating 
vagal afferents via 5HT3 receptors.  
 
Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause 
a release of 5HT in the area postrema, located on the floor of the fourth  ventricle, and this 
may also promote emesis through a central mechanism. Thus, the effect of Ondansetron in 
the management of the nausea and vomiting induced by cytotoxic chemotherapy and 
radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the 
peripheral and central nervous system. The mechanisms of action in post-operative nausea 
and vomiting are not known but there may be common pathways with cytotoxic induced 
nausea and vomiting. The role of Ondansetron in opiate-induced emesis is not yet 
established. 
 
Pharmacokinetic data 
 
Bioavailability              :  High 
 
Protein binding             :  70 – 76% (plasma protein binding) 
 
Absorption                    :  Ondansetron is well absorbed after oral administration and             
                                          Undergoes limited first pass metabolism. 
 
Metabolism                   :  Metabolized in the liver by hydroxylation followed by                  
                                          Glucronide CYP 3A4.    
 
Excretion                      :  Renal and fecal 
 
Half life                       :  Males       -   2.1 to 4.5 hr 
                                        Females   -   1.9 to 6.24 hr 
 
Clearance                   :  0.38 L/h/kg [Normal adult volunteers (19 – 40 yrs)] 
                                       0.32 L/h/kg [Normal adult volunteers (61 – 74 yrs)]  
                                       0.26 L/h/kg [Normal adult volunteers (> or = 75 yrs)]                  
 
Toxicity                      :  Low blood pressure and fainting, sudden blindness, severe  
                                       Constipation. 
 
Contraindication       :  Hypersensitivity to any component of the tablets. 
 
Storage                       :  Do not store above 25ºC. Store in the original package. 
 
Shelf life                     :  2 years 
 
 
Uses                            :  It is a 5HT3 receptor antagonist used mainly as the prevention of 
nausea and vomiting associated with emetogenic cancer chemotherapy, post operation, and 
radiation. Also used for the treatment of postoperative nausea and vomiting. 
 
Commercial formulation:  Zofran ODT- 4 mg (GlaxoSmithKline) 
 
 
 
 
 
 
 
 
 
 
 
2.4. POLYMER PROFILE41  
 
CROSCARMELLOSE SODIUM 
Structure 
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Empirical formula :  Cross linked polymer of carboxy methyl cellulose sodium. 
Molecular weight :  90000 – 700000 
Chemical name :  Cellulose, Carboxy methyl ether, Sodium salt 
Functional category :  Tablet and capsule superdisintegrant 
Description  :  CCS occurs as an odorless, white or grayish – white powder. 
Melting point  :  Browns at approximately 227ºC and chars at approximately 252ºC.          
Solubility  : Insoluble in water, although Croscarmellos swells to 4-8 times its                                                      
original volume on contact with water. Practically insoluble in acetone, ethanol and toluene.  
Density  :  1.543g/cm3 
Chemical properties :  Croscarmellose sodium is a cross linked polymer of carboxy methyl 
cellulose sodium. It is a stable though hygroscopic material. It is not compatible with strong 
acids or with soluble salts of iron and some other metals such as aluminium, mercury and 
zinc. 
Uses   :  It is used in oral pharmaceuticals as disintegrant for capsules tablets 
and granules. In tablet formulations, croscarmellose sodium may be used in direct 
compression or wet granulation processes. croscarmellose sodium at concentrations up to 5% 
w/w may be used as a tablet disintegrant, although normally 2% w/w is used in tablets 
prepared by direct compression and 3% w/w in tablets prepared by wet granulation process.   
 
 CROSPOVIDONE41 
Structure 
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Molecular formula                :  (C6H9NO) n 
Molecular weight                  :  >1000000 
Chemical name                     :  1-Ethenyl-2-pyrollidone homopolymer 
Functional category              :  Tablet superdisintegrant 
Description                            :  A white to creamy – white, finely divided, free flowing                     
                                                  nearly odourless, hygroscopic powder. 
Solubility                               :  Practically insoluble in water, soluble in most organic  
                                                  Solvents. 
Melting point                        :  Softens at 150ºC 
Density                                  :  1.22g/cm3 
Chemical properties      : Crospovidone is water – insoluble synthetic cross linked 
homopolymer of N- vinyl -2- pyrolidine. Crospovidone is compatible with wide range of 
inorganic salts, natural and synthetic resins, and other chemicals. 
Pharmaceutical applications                                    
1. It is water – insoluble tablet disintegrant and dissolution agent used at 2 – 5% 
concentration in tablets prepared by either direct compression or dry granulation method. 
2. It can be used as a solubility enhancer with the technique of co-evaporation. 
3. It can be used to enhance the solubility of poorly soluble drugs. 
4. The drug is absorbed on to crospovidone in the presence of a suitable solvent and the 
solvent is then evaporated. This technique results in faster dissolution rate. 
5. It rapidly exhibits high capillary activity and pronounced hydration capacity, with little 
tendency to form gels. 
 
TARTARIC ACID41 
  
 
                                   
Molecular weight             :  150.1 
Chemical name                : Tartaric acid is (2R, 3R) - 2, 3 – dihydroxy butanedioic acid. 
Molecular formula          :  It contains not less than 99.5% and not more than 101.0% of  
                                              C4H6O6, calculated on the dried basis. 
Description                       :  Colourless crystals or White or almost White crystalline                         
                                              powder.  
Application 
1. Used in beverages, confectionery, food products and pharmaceutical formulations as 
an acidulant.    
2. It is used as a combination with bicarbonates as the acid component of effervescent 
granules, powders and tablet. 
3. It is also used as a sequestering agent and an antioxidant synergist.      
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPARTAME41 
Structure 
                               
 
 synonyms                      :  3-Amino-N-(a carboxyphenethyl) succcinamic acid N-methyl    
                                          ester, 3-Amino-N-(a-   methoxycabonyl phenethyl)  succinamic               
                                          acid. 
Chemical name             :  N-a-L-Aspartyl-L-phenylalanine 1-methyl ester. 
Empirical formula        :  C14H18N2O5 
Molecular weight          :  294.31 
Description                    :  Aspartame occurs as an off white almost odourless crystalline  
                                            powder with an intensely sweet taste. 
Solubility                        :  Slightly soluble in ethanol (95%),sparingly soluble in water. 
Functional category      :  Sweetening agent 
 
Pharmaceutical applications 
1. Aspartame is used as an intense sweetening agent in beverage products, food 
products, table top sweeteners and in pharmaceutical preparations including tablets, 
powder mixes and vitamin preparations. 
2. It enhances flavor systems and can be used to mask some unpleasant taste 
characteristics the approximate sweetening power is 180-200 times that of sucrose. 
3. Therapeutically, aspartame is used in the treatment of sickle cell anemia. 
 
 
 
 
 
 
 
 MANNITOL41 
Structure 
                              
                                          
 
                                    
Synonym                   : Cordycepic acid; E421; 1,2,3,4,5,6,- hexanehol; manita;  
                                     mauna  sugar; mannite; pearlitol. 
 
Chemical name         : D – Mannitol 
 
Empirical formula    : C6H14O6 
 
Molecular weight      : 187.17 
 
Solubility                    :   Solubility at 20ºC.  
                                        Alkali- Soluble 
                                        Ethanol (95%) - 1 in 83 
                                        Ether - Practically insoluble 
                                        Water - 1 in 5.5 
Stability                      :  Mannitol is stable in dry state. 
 
Storage                       :  Stored in a well closed container in a cool, dry place. 
 
Functional category  : Sweetening agent, tablet and capsule diluent, tonicity  
                                      agent, Vehicle (bulking agent) for hydrophilized preparations. 
 
 
 
 
                                       Pharmaceutical applications 
1. In pharmaceutical preparations it is primarily used as a diluent (10 – 90 % w/w) in 
tablet formulations where it is of particular value since it is not hygroscopic and may 
thus be used with moisture sensitive active ingredients. 
2. Mannitol may be used in direct compression tablet applications for which the      
            granular and spray dried forms are available. 
3. It is used in the manufacture of chewable tablet formulations because of its     
negative heat of solution, sweetness and mouth feel.      
4. Therapeutically, mannitol administrated parenterally is used as an osmotic  diuretic, 
diagnostic agent for kidney functioning, as an adjunct in the treatment of    
      acute renal failure. 
5. It is used as a plasticizer in soft gelatin capsules, as a component of sustained release 
tablet formulations, and as a carrier in dry powder inhalers.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TALC41  
Synonym                    :    Magsil Osmanthus, Magsil star, purtalc, steatite 
Description                :     It is a very fine, white to greyish-white colored, odorless,   
                                         impalpable, unctuous powder. It adheres to the skin, is soft to   
                                         touch, and free from grittiness. 
Solubility                    :    Practically insoluble in dilute acids and alkalies, organic  
                                         solvents and water. 
Stability                      :    Talc is stable material. 
Storage conditions     :    It should be stored in a well-closed container in a cool place. 
Applications               :   It is used as a lubricant in solid dosage forms (1-10%),in topical   
                                         preparations as dusting powder (90-99%). 
Functional category  :     Glidant, tablet and capsule lubricant, anti-cracking agent. 
Incompatibilities       :    Incompatible with quaternary ammonium compounds. 
Safety                         :    Following oral ingestion talc is not absorbed systemically and  
                                         may thus be regarded as an essentially non-toxic material.  
                                         Intranasal or IV abuse of products containing talc.  
 
 
 
 
 
 
 
 
 
 
 
 MAGNESIUM STEARATE41 
Structure 
 
 
 
 
Synonym                :   Magnesium octadecanoate, octadecanoic acid, magnesium salt,                         
                                    stearic acid. 
Chemical name      :  Octadecanoic acid magnesium salt 
Emperical formula:  C36H70MgO4 
Molecular formula:  591.34 
Description             :  Magnesium stearate is a very fine, light white, precipitated or  
                                    Milled, impalpable powder of low bulk density, having a faint     
                                    odour of stearic acid and a characteristic taste. The powder is  
                                    Greasy to touch and readily adheres to the skin. 
Solubility                :  Practically insoluble in ethanol, ethanol (95%), ether and water 
                                   Slightly soluble in warm benzene and warm ethanol (95%) 
Stability and Storage conditions:  Magnesium stearate is stable and should be in a well  
                                                          Closed container in a cool, dry place. 
 
Pharmaceutical applications 
1. Magnesium stearate is widely used in cosmetics, foods and pharmaceutical 
formulations. 
2.  It is primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25% and 5% w/w  
3. It is also used in barrier creams.   
 
 
 
 Functional category :  Glidant, tablet and capsule lubricant, anti-cracking agent. 
Applications             :   It is used as a lubricant in solid dosage forms (1-10%), in       
                                       topical   preparations as dusting powder (90-99%). 
 
Description        :    It is a very fine, white to grayish-white colored, odorless, impalpable, 
unctuous powder. It adheres to the skin, is soft to touch, and free from grittiness. 
Solubility              :   Practically insoluble in dilute acids and alkalis, organic solvents, and 
water. 
Stability                    :  Talc is stable material. 
Storage conditions   :  It should be stored in a well-closed container in a cool place. 
Incompatibilities      :  Incompatible with quaternary ammonium compounds. 
Safety                       : Following oral ingestion talc is not absorbed systemically and may thus 
be regarded as an essentially non-toxic material. Intranasal or IV abuse of products 
containing talc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                3. RESEARCH ENVISAGED 
 
3.1. AIM OF PRESENT STUDY 
 
Difficulty in swallowing (dysphagia) is a common problem of all age groups, 
especially the elderly and pediatrics, because of physiological changes associated with those 
groups. Other categories that experience problems in using conventional oral dosage forms 
include the mentally ill, uncooperative and patients suffering from nausea, motion sickness, 
sudden episodes of allergic attack or coughing. Sometimes it may be difficult to swallow 
conventional products due to non-availability of water. These problems led to the 
development of a novel type of solid oral dosage form called orodispersible tablet, which 
disintegrates/dissolves rapidly in saliva without the need of drinking water. 
 
The benefits in terms of patient compliance, rapid onset of action, increased 
bioavailability and good stability make these tablets popular as a dosage form of choice in the 
current market. Some drugs are in such cases bioavailability of drug is significantly greater 
than those observed from conventional tablet dosage form.  
 
The basic approach used in the development of the ODTs is the use of 
superdisintegrants. Many approaches have been developed to manufacture ODTs. These 
include vacuum drying direct compression, lyophilization and molding. The direct 
compression method is inexpensive and convenient for producing tablets of sufficient 
mechanical strength. 
 
Antiemetics are the agents which can block nausea and vomiting sensations, which 
are frequently encountered with chemotherapy, radiation therapy, and post operative inducing 
nausea and vomiting. Ondansetron hydrochloride is a selective serotonin 5-HT3 receptor 
antagonist indicated for the prevention of nausea and vomiting and reported to be well 
absorbed from the gastrointestinal tract. 
 
In the present study, orodispersible tablets of ondansetron hydrochloride, are designed 
by using natural polymer (Treated agar) and synthetic polymers namely crospovidone and 
croscarmellose sodium. Effervescent substances like sodium bicarbonate and tartaric acid 
accelerated the superdisintegrant action and mask the bitter taste of ondansetron 
hydrochloride.  The designed tablets were evaluated for thickness, hardness, friability, weight 
variation, in vitro dispersion time, wetting time, water absorption ratio, disintegration time, 
drug content uniformity, in vitro dissolution rate (in pH 6.8 phosphate buffer), short term 
stability and drug excipient interactions (IR spectroscopy).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2. PLAN OF WORK 
 
The present work was carried out to prepare and evaluate ondansetron hydrochloride 
orodispersible tablets using different polymers in various concentrations. This work was 
carried out as outlined below. 
 
1. Precompression parameters 
 
2. Preparation of  orodispersible tablets 
 
3. Physico-chemical evaluation  
a. Thickness 
b. Hardness 
c. Friability 
d. Weight variation 
e. In vitro dispersion time 
f. Wetting time 
g. Water absorption ratio 
h. Disintegration time 
i. Drug content uniformity 
 
4. In vitro drug release studies  
 
5. Stability studies  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. MATERIALS AND INSTRUMENTS 
Table 2: Materials used 
 
S.No 
 
Materials 
 
Resources 
 
1. 
 
Ondansetron hydrochloride 
 
Madras Pharmaceuticals Chem Limited 
Chennai 
 
2. 
 
Sodium bicarbonate 
 
SDFCL Fine Chem Limited , Mumbai 
 
3. 
 
Tartaric acid 
 
SDFCL Fine Chem Limited , Mumbai 
 
4. 
 
Treated agar 
 
Rea Chem Laboratory Chemical, Chennai 
 
5. 
 
Croscarmellose sodium 
 
Mingatai Chemicals Co.Ltd,  Taiwan 
 
6. 
 
Crospovidone 
 
ISF  Technologies,  Chennai 
 
7. 
 
Aspartame 
 
Nutra  sweet  company, Mumbai 
 
8. 
 
Orange  1208 
 
Firminch  Ltd., Mumbai 
 
9. 
 
 
DEC ( corn starch : mannitol ) 
 
Rea Chem Laboratory Chemical, Chennai 
 
10. 
 
 
Magnesium stearate 
 
Vijlak Pharma Ltd., Hyderabad 
 
11. 
 
 
Talc 
 
SDFCL Fine Chem Limited , Mumbai 
LIST OF INSTRUMENTS USED 
Table 3: Instruments used 
  
Sl.No 
 
 
Instruments 
 
Company name 
 
1. 
 
Electronic Weighing Balance 
 
Shimadzu Corporation , Japan 
 
2. 
 
Sieves 
 
Jayanth Test Sieves, Mumbai 
 
3. 
 
Bulk Density And Tapped 
Density Apparatus 
 
Electro Lab, Mumbai 
 
4. 
 
FTIR ( Fourier Trnsform 
Infrared Spectrometer ) 
 
Jasco Model, Japan 
 
5. 
 
RMG  Mixer 
 
Sreenex Machines Pvt. Limited, 
Hyderabad 
 
6. 
 
Rotary Tablet Compression 
Machine 
 
Remek , Gujarat 
 
7. 
 
Monsanto Hardness Tester 
 
TAB Machines, Mumbai 
 
8. 
 
Friability Tester 
 
Thermonik Campbell 
Electronics, Mumbai 
 
9. 
 
Vernier Calliper 
 
Eletro Lab, Mumbai 
 
10. 
 
Disintegration Test 
Apparatus 
 
Electro Lab, Mumbai 
 
11. 
 
Dissolution Test Apparatus 
 
Electro Lab TDT-08L, Mumbai 
 12. 
 
Double Beam UV 
Spectrophotometer 
 
Syntronics-pc based double 
beam spectrophotometer 
2202,Mumbai 
 
13. 
 
Stability Chamber 
 
Thermolab Scientific 
Equipments Pvt.Ltd.,Mumbai 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         5. EXPERIMENTAL INVESTIGATION 
 
 
5.1. PREPARATION OF STANDARD CURVE FOR ONDANSETRON 
HYDROCHLORIDE 
 
PREPARATION OF PH 6.8 BUFFER (phosphate buffer) 42 
27.218 gm of potassium dihydrogen orthophosphate was dissolved in 1000 ml of distilled 
water. And to prepare 0.1 N sodium hydroxide solution. Then from this Potassium 
dihydrogen orthophosphate solution 250 ml was taken and mixed with 112 ml of 0.1 N 
Sodium hydroxide solution. Finally to make up 1000 ml by using distilled water. 
 
PREPARATION OF STANDARD CURVE FOR ONDANSETRON 
HYDROCHLORIDE 
 
100 mg of ondensetron hydrochloride was accurately weighed and dissolved in small portion 
of phosphate buffer pH6.8 in a 100 ml of volumetric flask and the volume was made upto 100 
ml with buffer. This is the primary stock solution. From the primary stock solution 10 ml was 
accurately pippetted out and transferred into a 100 ml volumetric flask. Then the volume was 
made upto 100 ml with buffer. From the secondary stock solution aliquots equivalent to 2-10 
mcg (2ml,4ml,6ml,8ml, and 10 ml) were pippeted out into a series of 10 with buffer. The 
absorbance of above set solutions were against the phosphate buffer pH 6.8 as blank at 
248nm40. Then calibration curve was plotted taking concentration on X-axis and absorbance 
on Y-axis. 
 
 
 
 
 
 
 
 
 
 TABLE NO: 4 
STANDARD CURVE FOR ONDANSETRON HYDROCHLORIDE IN PHOSPHATE 
BUFFER PH 6.8 
 
 
 
 
Concentration in  
(µg/ml) 
 
Absorbance at  
248 nm 
 
0 
 
0 
 
2 
 
0.083 
 
4 
 
0.167 
 
6 
 
0.248 
 
8 
 
0.324 
 
10 
 
0.401 
 
Slope 
 
0.041 
 
Correlation 
 
0.9994 
 
 
 
 
 
 
 
FIGURE – 4  
STANDARD CURVE OF ONDANSETRON HYDROCHLORIDE IN PHOSPHATE 
BUFFER pH 6.8 
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5.2. PREFORMULATION STUDIES 
 
              Preformulation study relates to pharmaceutical and analytical investigation carried 
out proceeding and supporting formulation development efforts of the dosage form of the 
drug substance. Preformulation yields basic knowledge necessary to develop suitable 
formulation for the toxicological use. It gives information needed to define the nature of the 
drug substance and provide frame work for the drug combination with pharmaceutical 
excipients in the dosage form. Hence, the following preformulation studies were performed 
on the obtained sample of drug. 
 
a) Bulk Density (Db) 2 
 It is the ratio of total mass of powder to the bulk volume of powder. It was measured 
by pouring the weighed powder into a measuring cylinder and initial weight was noted. This 
initial volume was called the bulk volume. From this the bulk density was calculated 
according to the formula mentioned below. It is expressed in gm/ml and is given by                                  
                                 Bulk density (Db) = Mass (M) / Bulk volume (Vb) 
 
Where, M is the mass of powder,  Vb is the bulk volume of the powder.  
 
b) Tapped density (Dt) 2 
It is the ratio of total mass of the powder to the tapped volume of the powder. Volume 
was measured by tapping the powder for 750 times and the tapped volume was noted if the 
difference between these two volumes is less than 2%. If it is more than 2%, tapping is 
continued for 1250 times and tapped volume was noted. Tapping was continued until the 
difference between successive volumes is less than 2 % (in a bulk density apparatus). It is 
expressed in gm/ml and is given by 
                                                      
                          Tapped density (Dt) = Mass (M) / Tapped volume (Vt) 
 
            Where, M is the mass of powder; Vt is the tapped volume of the powder. 
 
 
 
 
C) Angle of repose2 
                 The angle of repose of powder was determined by the funnel method. The 
accurately weighed powder was taken in a funnel. The height of the funnel was adjusted in 
such a way that the tip of the funnel just touches the apex of the heap of the powder. The 
powder was allowed to flow through the funnel freely onto the surface. The diameter of the 
powder cone was measured and angle of repose was calculated using the following equation.                                    
                                                      θ = tan-1 h / r 
 Where, h and r are the height and radius of the powder cone, respectively       
 
                     Table 5: Flow properties and corresponding angle of repose 
 
 
ANGLE OF REPOSE 
 
FLOW  PROPERTY 
25 – 30 Excellent 
31 – 35 Good 
36 – 40 Fair 
41 – 45 Passable 
46 – 55 Poor 
56 – 65 Very poor 
> 66 Extremely poor 
                                       
  d) Carr’s Index or % compressibility2 
It is indirectly related to the relative flow rate, cohesiveness and particle size. It is 
simple, popular and fast method of predicting powder flow characteristics. It is based on the 
apparent bulk density and the tapped density, the percentage compressibility of the the bulk 
drug was determined by the following formula. 
 
 
% compressibility index =        Tapped bulk density – Initial bulk density  X 100 
                                                                       Tapped bulk density 
 
Table 6: Flowability based on compressibility index 
 
Carr’s index Type of flow 
5 – 15 Excellent 
12 – 18 Good 
18 – 23 Poor 
35 – 38 Very poor 
> 40 Extremely poor 
 
e) Hausner’s ratio2 
The ratio of the tapped density to bulk density is called as hausner ratio. It is an 
indirect index of ease of powder flow. It is calculated by the following formula. 
                  Hausner ratio = Tapped density (Dt) / Bulk density (Db) 
Lower hausner ratio (1.25) indicates better flow properties than higher ones (1.25)       
                        
Table 7: Scale of flowability based on Hausner’s ratio 
 
 
HAUSNER’S RATIO 
 
TYPE OF FLOW 
Less than 1.25 Good flow 
1.25 – 1.5 Moderate 
More than 1.5 Poor flow 
                        
 
 
 
 
 
 
 
 
 TABLE NO – 8:    PRECOMPRESSION EVALUATION 
 
 
 
 
FORMULATIONS 
PARAMETERS 
Bulk 
density 
(gm/cm3) 
Tapped 
density 
(gm/cm3) 
Angle of 
repose (θ) 
Carr’s 
index(%) 
Hausner’s 
ratio 
F1 0.463±0.003 0.543±0.002 34.96±0.051 14.81±0.015 1.18±0.010 
F2 0.468±0.005 0.545±0.003 31.31±0.032 14.88±0.085 1.17±0.010 
F3 0.471±0.013 0.569±0.006 31.08±0.091 14.30±0.135 1.18±0.010 
F4 0.481±0.041 0.561±0.001 31.24±0.250 14.31±0.120 1.15±0.030 
F5 0.540±0.010 0.613±0.009 30.25±0.230 11.61±0.162 1.23±0.105 
F6 0.552±0.002 0.632±0.010 30.92±0.023 12.51±0.023 1.14±0.001 
F7 0.568±0.001 0.663±0.001 29.51±0.022 14.53±0.250 1.12±0.038 
F8 0.414±0.005 0.479±0.008 28.83±0.031 14.26±0.300 1.16±0.005 
F9 0.395±0.040 0.444±0.005 28.25±0.054 13.17±0.100 1.15±0.015 
F10 0.372±0.001 0.310±0.031 28.17±0.061 13.30±0.064 1.15±0.065 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.3. DRUG EXCIPIENT COMPATABILITY STUDY BY FTIR ANALYSIS 
              
            Compatibility of the drug with excipients was determined by FT-IR spectral analysis, 
this study was carried out to detect any changes on chemical constitution of the drug after 
combined it with the excipients.  
 Infrared spectra for pure ondansetron hydrochloride, drug with polymers, and best 
formulation that determined to check the intactness of the drug in the formulation. 
 
The TABLE NO- 9  shows the wave number for the characteristic bands in the infrared 
spectra of pure ondansetron hydrochloride. 
 
 
 
TABLE NO – 9 
Characteristic peaks of Ondansetron hydrochloride 
 
Wave number in cm-1 
 
Characteristic bands 
 
1622 C=O Stretching 
2970,2850 CH Stretching of CH3 
1375 CH Bending vibration of CH3 
3498 NH Stretching 
            
 
 
 
 
 
 
 
 
Infrared spectra for the pure drug, for the carriers and for the best formulations are shown in 
FIGURE – 5 
 
                                                         
                                                               FIGURE-5 
IR SPECTRA OF ONDANSETRON HYDROCHLORIDE 
 
 
 
 
 
               COMPATIBILITY STUDY OF DRUG WITH POLYMER      
 
 
 
       
                                                            FIGURE-6 
IR SPECTRA OF ONDANSETRON HYDROCHLORIDE+TREARED AGAR 
 
 
 
 
 
 
 
                                                                 FIGURE-7 
       IR SPECTRA OF ONDANSETRON HYDROCHLORIDE +CROSPOVIDONE 
 
 
 
 
 
 
 
 
 
                                 
                                                               FIGURE-8              
IR SPECTRA OF ONDANSETRON HYDROCHLORIDE+CROSCARMELLOSE            
                                                                SODIUM 
 
 
 
 
 
 
 
 
 
                                            
                                                      FIGURE-9 
                       IR  SPECTRA OF BEST FORMULATION (F10) 
 
 
 
 
 
 
 
 
 
 
 
5.4. PREPARATION OF ONDANSETRON HYDROCHLORIDE ORODISPERSIBLE 
TABLETS  
 
Preparation of Directly Compressible Excipient17 
The directly compressible excipient (DCE) was prepared using a local variety of food 
grade corn starch along with mannitol in 1:1 ratio using 10% w/w starch paste for 
granulation.  
 
Method 
  All the ingredients were powdered separately in a dry, clean porcelain mortar and 
passed through # 60 mesh sieve and mixed well in geometrical ratio. Granulating fluid, starch 
paste (10% w/w)  is  added  to  the  powder  mixture  in small quantities, while mixing  
thoroughly  after  each  addition until a coherent mass was formed. Then it was  passed  
through  #  44  mesh  sieve  and  the  wet  granules  were  spread  on  a  paper and  dried  in  
hot  air  oven at 55-60ºC. The dried granules were then passed through # 36 mesh sieve. 
 
Preparation of treated agar17 
Treated agar (TAG) powders were prepared by taking 10 gm agar powder in distilled 
water (100 ml) and stirring at 50 rpm with a three- bladed mechanical stirrer for one day. This 
causes water absorption and swelling. Then the liquid was poured in a large petri-dish and 
allowed   for drying up to three days in incubator at 37±1ºC and then the mass was pulverized 
and sifted through # 80 mesh sieve . 
 
 
 
 
 
 
 
 
 
 
 
 
PREPARATION OF ORODISPERSIBLE TABLET 17 
Orodispersible tablets of Ondansetron hydrochloride were prepared by effervescent 
method according to the formula. All the ingredients were passed through # 60 mesh sieves 
separately. The drug and directly compressible excipient were mixed by adding small portion 
of each at a time and blending it to get a uniform mixture and kept aside. Sodium bicarbonate 
and tartaric acid were pre-heated at a temperature of 80ºC for 2 h to remove absorbed/residual 
moisture and thoroughly mixed in a mortar to get a uniform powder and then added to the 
above blend. Then the other ingredients were mixed in geometrical order but magnesium 
stearate and purified talc were added at the last and mixed for further two minutes. The blend 
was compressed using 9 mm flat round punches to get tablets of 200 mg weight on 10-station 
rotary tablet machine. A batch of 60 tablets was prepared for all the designed formulations.  
 
                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                           TABLE NO: 10 
FORMULATION DESIGN FOR ONDANSETRON HYDROCHLORIDE TABLETS 
 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Drug    4   4   4   4   4   4  4  4  4   4 
NaHCO3  18 18  18 18 18 18 18 18 18 18 
Tartaric acid  18 18 18 18 18 18 18 18 18 18 
Treated agar  _ 10 15 20   _   _   _   _   _    _ 
Crospovidone  _   _  _  _  10  15  20  _  _   _ 
Croscarmellose sodium  _   _  _  _   _   _   _   10   15   20  
Aspartame    8    8     8    8     8     8    8    8   8   8 
Orange 12809  3  3  3  3  3  3  3  3  3  3 
Magnesium stearate  2  2  2  2  2  2  2  2  2  2 
Talc  1  1  1  1  1  1  1  1  1  1 
DCE 146 136 131 126 136 131  126  136 131  126 
Total weight 200 200 200 200 200 200 200 200 200 200 
 
 
 
 
 
 
 
 
 
5.5. PHYSICO CHEMICAL EVALUATION  
 
A. Weight variation 26 
 
Twenty tablets were taken and their weights were determined individually and 
collectively on a digital weighing balance. The average weight of one tablet was determined 
from the collective weight. Average weight was compared with the individual weight and the 
percentage deviation of individual tablet was calculated. 
 
Table 11 : Weight variation limit as per IP 
 
Average weight of Tablet 
 
Percentage Deviation 
80 mg or less ± 10% 
More than 80 mg but 
less than 250 mg 
 
± 7.5% 
250 mg or more                ± 5% 
 
B. Thickness 4 
The thickness of the tablets was determined by using vernier caliper of Electro lab 
model. Five tablets are randomly selected from each batch. It is expressed from mm and the 
average values were calculated. 
C. Hardness 4  
Hardness was determined by taking five tablets from each formulation and was 
measured by using Monsanto hardness tester. The hardness was measured in terms of kg/cm3. 
D. Friability 43  
The friability of the tablet was measured using an Roche friabillator  (Electro lab, 
India).Twenty reweighed tablets were rotated at 25 rpm for 4 rpm and dropping the tablets at 
a height of 6 inches at each revolution and the tablets were subjected to 100 revolutions. The 
tablets were then dedusted using soft muslin cloth and reweighed and the percentage of 
weight loss was calculated. The percentage friability of the tablets were measured as per the 
following formula. 
 
Percentage friability =    (Initial weight – final weight/ Initial weight) ×100  
                                                            TABLE NO: 12 
PHYSICOCHEMICAL EVALUATION OF ONDANSETRON HYDROCHOLORIDE  
 
 
Formulation 
code 
 
Weight 
variation 
(mg) 
 
Thickness 
(mm) 
 
Hardness 
(kg/cm2) 
 
Friability 
(%) 
F1 200.4±0.84 2.35±0.03 2.20±0.10 0.831±0.01 
F2 200.2±1.35 2.34±0.01 2.13±0.20 0.781±0.03 
F3 200.1±0.06 2.34±0.03 2.13±0.21 0.836±0.07 
F4 200.3±0.94 2.32±0.01 2.30±0.17 0.747±0.08 
F5 200.1±0.05 2.31±0.01 2.33±0.11 0.814±0.04 
F6 200.3±0.94 2.34±0.01 2.40±0.26 0.832±0.01 
F7 200.2±0.05 2.32±0.00 2.02±0.15 0.780±0.10 
F8 199.9±1.10 2.33±0.01 2.16±0.11 0.907±0.08 
F9 200.2±1.30 2.34±0.00 2.20±0.10 0.941±0.04 
F10 199.8±1.34 2.32±0.01 2.26±0.05 0.922±0.01 
 
 
 
 
E. In vitro dispersion time 33 
In vitro dispersion time was measured by dropping a tablet in a measuring cylinder 
containing 10ml of simulated saliva fluid of pH 6.8. After dropping a tablet in the simulated 
saliva fluid, the tablet started to swell quickly, broke and followed by dispersed. Five tablets 
from each formulation were randomly selected and in vitro dispersion time was performed 
and it was expressed in seconds. 
 
F. Wetting time25 
Wetting time is closely related to the inner structure of the tablets and to the 
hydrophilicity of the excipient. A linear relationship exists between wetting time and 
disintegration time. Thus wetting is the important step for disintegration process to take 
place. 
 A piece of tissue paper folded double was placed in a petri plate (internal diameter is 
6.5cm) containing 6ml of purified water. A tablet having a small amount of Eosine dye 
powder on the upper surface was placed on the tissue paper. The time required to develop a 
red color on the upper surface of the tablet was recorded as the wetting time.  
 
G. Disintegration time31 
Disintegration time was measured using disintegration test apparatus. A tablet was 
placed in each six tube of the basket. The basket with the bottom surface is made up of 
stainless – steel screen (mesh no. 10) was immersed in water maintained at 37°C as the 
disintegration fluid and the paddle at 100rpm as stirring element was used. The time taken for 
complete disintegration of the tablet with no palatable mass remaining in the apparatus was 
measured in seconds. 
 
H. Water absorption ratio 25 
             A piece of double folded tissue paper was kept in a petri dish (internal diameter 5.5 
cm) containing 6 ml of purified water. The weight of tablet before keeping in petri-dish was 
noted as (Wb) and after completely wetted tablet in petriplate was noted as (Wa). The wetted 
tablet was removed and reweighed. Water absorption ratio, R was determined according to 
the following equation. 
 
R = 100 (Wa – Wb) / Wb 
  
            Where, Wb and Wa are before and after water absorption, respectively.  
 
I. Drug content 19 
Ten tablets from each batch were weighed and powdered. The required amount of the powder 
equivalent to 4 mg of ondansetron hydrochloride was dissolved in 100 ml of phosphate buffer 
pH6.8. From this solution 1 ml was taken and made up to 100 ml by using phosphate buffer 
pH6.8 and the solution was filtered by using whatmann filter paper. The solution was 
analysed for drug content at 248nm using UV visible spectrophotometer.   
 
 
 
 
       TABLE NO: 13 PHYSICOCHEMICAL EVALUATION OF ONDANSETRON                    
                                                      HYDROCHOLORIDE  
 
Formulation 
code 
In vitro 
Dispersion 
time(sec) 
Wetting 
time(sec) 
Disintegration 
time(sec) 
Water 
absorption 
ratio 
Assay (%) 
F1 60.37±0.40 41.03±0.05 50.73±0.64 39.30±0.81 90.44±0.50 
F2 49.16±0.15 35.83±0.73 42.26±0.35 33.06±0.51 96.54±0.48 
F3 43.36±0.40 32.66±0.57 40.56±0.45 43.66±0.41 97.37±0.57 
F4 40.52±0.44 30.23±0.32 36.13±0.20 33.56±0.58 100.85±0.16 
F5 38.56±0.77 33.23±0.25 34.40±0.60 33.70±0.34 99.52±0.17 
F6 35.26±0.28 31.63±0.30 32.18±0.23 27.96±0.95 100.48±0.22 
F7 32.41±0.17 28.46±0.30 29.63±0.40 32.76±0.68 101.29±0.34 
F8 30.37±0.22 30.40±0.36 25.26±0.17 31.36±0.32 102.55±0.48 
F9 28.44±0.50 28.30±0.40 22.15±0.17 30.50±0.50 100.15±0.27 
F10 26.45±0.41 26.26±0.30 20.27±0.40 29.50±0.30 99.96±0.06 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.6 IN VITRO DRUG RELEASE STUDY 17 
 
In vitro dissolution of the orodispersible tablets was studied in USP XXIII type-II 
dissolution test apparatus (Electro lab, model: TDT-06N) employing a paddle stirrer at 50 
rpm using 900 ml of pH 6.8 phosphate buffer at 37±0.5o C as dissolution medium. One tablet 
was used in each test. Aliquots of dissolution medium were withdrawn at specified intervals 
of time and analyzed for drug content by measuring the absorbance at 248 nm. The volume 
withdrawn at each time interval was replaced with fresh quantity of dissolution medium. 
Cumulative percent of the drug released was calculated and plotted against time. The results 
obtained are given in TABLE NO: 14. 
 
   Dissolution Condition: 
Apparatus  : USP XX111 paddle apparatus 2. 
RPM   : 50 
Medium  : phosphate buffer (pH 6.8) 
Sampling Interval : Every 5 minute.  
Sampling Volume : 5 ml. 
             Study Period                   :  30 min 
 
 
 
 
 
 
 
 
 
                                                    
                                          
 
        
  
                                                       TABLE NO: 14 
IN VITRO DRUG RELEASE DATA (F1-F10) 
 
Formulation 
code 
% Cumulative release 
5 min 10 min 15 min 20 min 25 min 30 min 
F1 56.15 62.08 62.95 64.37 65.80 66.69 
F2 66.14 80.60 82.66 84.19 85.18 85.63 
F3 66.98 82.94 83.92 85.46 86.45 87.45 
F4 72.19 84.63 86.71 88.80 89.27 90.28 
F5 67.80 81.78 84.94 87.57 88.03 90.67 
F6 77.15 80.07 89.63 92.28 93.85 94.89 
F7 74.47 90.26 92.26 94.50 95.00 96.59 
F8 74.98 84.21 87.93 84.48 91.04 92.61 
F9 76.65 89.74 91.31 92.88 94.46 95.50 
F10 77.78 91.45 95.20 96.79 98.39 99.49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          FIGURE 10 
IN VITRO DRUG RELEASE FOR F1,F2,F3 AND F4 
 
 
 
                     
 
                FIGURE 11:  IN VITRO DRUG RELEASE FOR F5,F6 AND F7 
 
 
                  
 
  
 
 
 
 
FIGURE 12:  IN VITRO DRUG RELEASE FOR F8,F9 AND F10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.7. Accelerated stability studies .23 
 
The goal of a stability program is not uniquely defined, but depends on the stage of 
development of the product in question. At the very onset of development, it is desired to 
know what the inherent stability of the drug substance is and what interactions with the 
excipients can be expected. On the analytical side, it is usually supported by an assay 
procedure, which helps in developing the stability program. 
 
The stability program varies from one dosage form to another and formulation to formulation. 
Accelerated stability studies are of great interest and are attractive as which can document 
satisfactory results under stressed conditions time saving can be achieved. 
The stability of this optimized formulation was known by performing stability studies for 
three months at accelerated conditions of 40°C±75 % RH on optimized formulation.  
 
The formulation was found to be stable, with insignificant change in the hardness, 
disintegration time, and in vitro drug release pattern. The results are presented in TABLE 
NO: 15. 
                                                     TABLE NO: 15 
STABILITY DATA FOR FORMULATION F10  
 
 
Parameters 
Time in months 
0 (Initial) 1st month 2nd month 3rd  month 
Hardness (kg/cm2) 2.93±0.02 2.92±0.01 2.89±0.01 2.86±0.01 
Disintegration time (sec) 23.63±1.46 23.45±1.01 23.38±0.05 24.30±0.17 
Drug content (%) 100.10±0.13 99.92±0.05 99.88±0.08 99.58±0.36 
In vitro drug release (%) 99.41±0.17 99.69±0.16 99.44±0.11 99.89±0.08 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. RESULTS AND DISCUSSION 
WEIGHT VARIATION 
The weight variation in all the ten formulation was found to be 199.8±1.34 to 200.4±0.84 
mg.  Formulations were with in pharmacopoeial limits with free flow of the powder blend 
and demonstrating the efficiency of compression of particles into tablets. 
 
HARDNESS  
The Hardness was maintained to be within 2.02±0.15 to 2.40±0.26 kg/cm2 as these tablets 
are rapidly disintegrating. No variation in the hardness was found which clearly indicates 
that the proper blending of the mixture for the preparation of orodispersible tablets. The 
prepared tablets in all the formulation possess good mechanical strength with sufficient 
hardness. 
       
      THICKNESS 
Thickness of all tablets prepared in the range of 2.31±0.01 to 2.35±0.03 mm was 
acceptable without much variation. 
 
      PERCENTAGE FRIABILITY 
Percentage Friability is below 1% in all the formulation and values obtained lies between 
0.747±0.08 to 0.941±0.04%. It indicated that of good mechanical resistance of the tablets. 
 
WETTING TIME 
The Wetting time was rapid in croscarmellose sodium followed by crospovidone, treated 
agar. The value lies between 26.26±0.30 to 41.03±0.05 sec. Fig. 13 depicts the relation 
between the concentration of superdisintegrants and wetting time.  It indicated that as 
concentration of disintegrant increases the time taken for wetting was reduced. Wetting 
time is used a parameter to correlate with disintegration time in oral cavity. This is an 
important criterion for understanding the capacity of disintegrants to swell in the presence 
of little amount of water. 
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FIGURE 13: WETTING TIME OF DIFFERENT SUPERDISINTEGRANTS WITH 
DIFFERENT CONCENTRATION  
 
 
 
DISPERSION TIME 
 
Further the tablets were subjected in vitro dispersion in which the time taken by the tablet to 
produce complete dispersion is measured. The values for all the ten formulations lie between 
26.45±0.41 to 60.37±0.40 sec. The in vitro dispersion time was rapid in croscarmellose 
sodium followed by crospovidone and treated agar. The comparative results are shown in the 
following figure 14. 
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FIGURE 14: DISPERSION TIME OF DIFFERENT SUPERDISINTEGRANTS WITH 
DIFFERENT CONCENTRATION 
 
 
DISINTEGRATION TIME 
The disintegration time for all the formulations lie between 20.276±0.402 to 50.73±0.646 sec. 
Fig.15 depicts the disintegration behavior of the tablets in water. This rapid disintegration of 
the oral dispersible tablets were due to penetration of saliva into the pores of the tablets, 
which leads to the swelling of super disintegrants to create enough hydrodynamic pressure 
for quick and complete disintegration of the tablet. Batch F10 was selected as best 
formulation containing croscarmellose sodium as superdisintegrant in 10% concentration. It 
was observed that less disintegration time of 20 sec was observed when croscarmellose 
sodium was used as superdisintegrant, may be due to swelling at faster rate upon contact with 
water and elimination of lump formation after disintegration when compared with 
crospovidone and treated agar. 
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FIGURE 15: DISINTEGRATION TIME OF DIFFERENT SUPERDISINTEGRANTS 
WITH DIFFERENT CONCENTRATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE  16: COMPARISON OF DISINTEGRATION TIME AND WETTING TIME 
OF BEST FORMULATED TABLET WITH MARKETED TABLET. 
 
 
 
 Finally the disintegration time of best formulation was compared with marketed formulation 
the results showed that formulated tablet disintegrated in 20 sec as compared to 34 sec for 
marketed Ondansetron tablet (ZOFER ODT). The formulation F10  was found to be the best, 
as this formulation showed less disintegration time and possessing good tableting properties.
  
 
The rapid drug dissolution might be due to easy breakdown of particles and rapid absorption 
of drug into the dissolution medium. This signifies that disintegrant concentration in 10% is 
suitable for the formulation of orodispersible tablets of ondansetron hydrochlorie. 
 
The various dissolution parameter values viz., percent drug dissolved in 4 min (D4), t50%  and 
t70% for promising formulations of 10% concentration of all the three different polymers (i.e) 
F4, F7,F10 were compared with the control shown in Table-16 and the dissolution profile 
depicted in fig 17. This data reveals that the F10 formulation shows  faster drug release 
compared to the commercial formulation (CF) based on t50% and  t70%  values in pH 6.8 
Phosphate buffer. The best formulation F10 compared with marketed formulation. 
 
TABLE 16: IN VITRO DISSOLUTION PARAMETERS IN pH 6.8 PHOSPHATE                     
BUFFER 
 
 
 
 
 
 
 
 
 
The Control formulation of (F1),10% concentration of superdisintegrants for (F4,F7,F10) and 
commercial formulation of in vitro cumulative drug release was shown in the fig 17. 
The best and marketed formulation is depicted as shown in fig 18. 
 
 
 
 
 
 
 
 
 
 
 
Formulation code t50% (min) t70%(min) D4(%) 
F1 7.49 10.49 55.30% 
F4 5.53 7.75 68.54% 
F7 5.17 7.23 75.705 
F10 5.02 7.03 74.16% 
CF 5.72 8.01 65.77% 
 FIGURE:17  PERCENTAGE CUMULATIVE DRUG RELEASE FOR F1,F4,F7,F10 
AND COMMERCIAL FORMULATION 
 
 
 
FIGURE 18: PERCENTAGE CUMULATIVE DRUG RELEASE FOR F10 AND 
MARKETED FORMULATION 
 
 
 
 
 
7. CONCLUSION 
 
 Orodispersible tablets of ondansetron hydrochloride is prepared by Direct compression 
method. The formulation F10 containing 10% of superdisintegrant (i.e) Croscarmellose 
sodium has shown best release with 99.46% at the end of 30 min. The effervescent mixture 
further assists in taste masking of Ondansetron hydrochloride. 
 
According to IR studies there is no incompatibility shown in F10. The formulation F10 was 
stable at 40°C±2ºC and 75%RH±5%RH. 
 
In conclusion formulation F10 achieved the targets of the present study such as, 
 
i) Not require water to swallow, but it should dissolve or disintegrate 
in the mouth in matter of seconds. 
ii) To mask the bitter taste. 
iii) Have a pleasant mouth feel. 
iv) Rapid dissolution of drug and absorption which may produce rapid, 
onset of action. 
v) Improved bioavailability. 
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ABSTRACT 
 
 
 
The purpose of this research work is to formulate and 
evaluate the Orodispersible drug delivery system of already used 
therapeutic molecule to enhance bioavailability and effectiveness 
of the drug. Among ODT drugs, the most promising antiemetic is 
Ondansetron hydrochloride & it was selected for the present 
study. Thus the objectives of the drug work were to formulate 
and evaluate Orodispersible tablets of Ondansetron 
hydrochloride, having adequate mechanical strength, rapid 
disintegration and fast action. Pre compression parameters like 
angle of repose, bulk density, tapped density, compressibility 
index & post compression parameters like wetting time, water 
absorption ratio, in-vitro disintegration and in-vitro dispersion 
time were studied. The hardness, friability and drug content of all 
the formulations were found to be with in the limits. The best 
formulation F10 have shown good disintegration time, dissolution 
time and dispersion time. The best promising formulation were 
also be found to be stable at 40°C±75 % . Finally the in-vitro drug 
released characteristics of best formulation was compared to 
commercial formulation. 
 
 
 
  
 
